# Lifecore Biomedical, Inc. \de\ (LFCR)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/lifecore-biomedical-inc-de/ JSON: https://steadybase.io/company/lifecore-biomedical-inc-de.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: LIFECORE BIOMEDICAL, INC. \DE\
- Ticker: LFCR (Nasdaq)
- SEC CIK: 0001005286
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Chaska, MN
- Fiscal year ends: May 25
- SEC filer category: Accelerated filer<br>Smaller reporting company
- Website: lifecore.com
- LinkedIn: https://www.linkedin.com/company/lifecore-biomedical
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $128.9M for the fiscal year ended May 25, 2025 (10-KT filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.html
- Operating income: -$17.2M for the fiscal year ended May 25, 2025 (10-KT filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.html
- Net income: -$38.7M for the fiscal year ended May 25, 2025 (10-KT filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.html
- SG&A: $44.0M for the fiscal year ended May 25, 2025 (10-KT filed Mar 16, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000009/0001005286-26-000009-index.html
- Employees: 406 as of May 25, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/lfcr-20250525.htm
- Shares outstanding: 37,905,846 as of Oct 28, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000046/0001005286-26-000046-index.html
- Auditor: Bdo Usa, P.C., Minneapolis, Minnesota, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/lfcr-20250525.htm

## Business

Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities.S.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/lfcr-20250525.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| May 25, 2025 | $128.9M | -$17.2M | -$38.7M | $44.0M |
| May 26, 2024 | $128.3M | -$8.8M | $12.0M | $40.5M |
| May 28, 2023 | $103.3M | -$21.8M | -$99.6M | $39.0M |
| May 29, 2022 | $111.3M | -$11.8M | -$116.7M | $34.7M |
| May 30, 2021 | $100.9M | -$8.8M | -$32.3M | $27.7M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/lifecore-biomedical-inc-de.json

## Officers and directors

- Paul Josephs, President and chief executive officer of Lifecore. LinkedIn: https://linkedin.com/in/paul-josephs-6b33b03. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000045/lfcr-2026q3xex991earningsr.htm
- Thomas D. Salus, Chief Legal & Administration. Source: Form 4 filed Apr 16, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000206220926000004/0002062209-26-000004-index.htm
- Christopher S. Kiper, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Humberto C. Antunes, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Jason Aryeh, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Katrina L. Houde, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Matthew E. Korenberg, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Nelson Obus, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Paul H. Johnson, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Ryan D. Lake, Named in proxy. LinkedIn: https://www.linkedin.com/in/ryan-d-lake-cpa-6abb544. Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm
- Joshua E. Schechter, Board member (per proxy). Source: DEF 14A filed Sep 18, 2025, https://www.sec.gov/Archives/edgar/data/1005286/000100528625000126/lfcr-20250918.htm

## Recent 8-K events

- Nov 5, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000049/lfcr-20261104.htm
- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000045/lfcr-20261104.htm
- Oct 20, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000040/lfcr-20261016.htm
- Sep 29, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000036/lfcr-20260924.htm
- Sep 28, 2026: Item 1.01, Entry into a material definitive agreement; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/ef20082009_8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm
- Jul 2, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000026/lfcr-20260629.htm
- Jun 5, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000023/lfcr-20260604.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lndc-20260506.htm
- Mar 16, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lndc-20260316.htm

## What management said

- "During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginni" Paul Josephs, president and chief executive officer of Lifecore (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000045/lfcr-2026q3xex991earningsr.htm

## Latest filings

- 8-K filed Oct 20, 2026: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000040/lfcr-20261016.htm
- 10-K filed Aug 7, 2025: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000108/lfcr-20250525.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000033/lfcr-20260630.htm
- DEF 14A filed Apr 24, 2026: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000012/lfcr-20260424.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/